الفهرس | Only 14 pages are availabe for public view |
Abstract As the COVID-19 pandemic persists, an increasing number of patients are suffering from loss of smell, which is now a well-known symptom of the disease. Loss of smell significantly impacts the quality of life of COVID-19 patients; therefore, its diagnosis and treatment should be prioritized. Unfortunately, the lack of a clear understanding of the molecular mechanisms of olfactory dysfunction has resulted in limited treatment options. The olfactory system exhibits unique neural plasticity that is not found in other parts of the central nervous system, with neurogenesis in the neuroepithelium and parts of the olfactory tract continuing throughout a person’s life. This suggests that certain interventions could help restore the sense of smell by awakening olfactory neurons or modulating neural function. OT is an intervention that improves olfactory function through frequent sniffing and/or exposure to strong odors. However, the gold standard for treating loss of smell remains unknown. Oral corticosteroids can often improve olfactory function;however, their effect is often short-lived and disappears with the discontinuation of treatment. Therefore, the use of oral corticosteroids is strongly contraindicated by the World Health Organization. However, long-term improvement has been reported with the use of intranasal steroids. So, this is randomized clinical trial was carried out in Suez Canal University Hospital at ENT department from February 2022 to July2022 to evaluate the efficacy of Fluticasone nasal spray and smell retraining therapy on post COVID-19 anosmia. |